YOLFTbeta
Orion Oyj A

Orion Oyj A

ORNAV · HE · Healthcare / Drug Manufacturers - General

102.80EUR+0.40 (+0.39%)

Price History

Full chart

Market Stats

Previous Close102.40
Open102.40
Day Range101.80 – 103.40
52-Week Range55.66 – 102.40
Volume3.64K
Market Cap14.16B
P/E (TTM)21.58
Forward P/E29.50
EPS4.68
Dividend Yield1.79%
Beta0.24
50-Day Avg84.71
200-Day Avg74.81

About

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Liisa Hurme Ph.D.
  • Employees4.21K
  • HeadquartersOrionintie 1A, Espo, Finland, 02200, Finland
  • Websitehttps://www.orionpharma.com

Leadership

  • Dr. Liisa Hurme Ph.D.President, CEO & Chairman of Executive Management Board · b. 1967
  • Mr. Rene Lindell M.Sc., Ph.D.CFO & Member of Group Executive Management Board · b. 1976
  • Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board · b. 1966
  • Prof. Outi Vaarala M.D., Ph.D.Executive VP of Research & Development and Member of the Exe. Mgmt. Board · b. 1962
  • Mr. Juhani Kankaanpaa M.Sc.Executive VP of Global Operations & Member of Executive Management Board · b. 1980
  • Mr. Niclas Lindstedt EMBA, M.Sc.Executive VP of Animal Health & Member of the Exe. Mgmt. Board · b. 1966
  • Mr. Hao Pan M.Sc.Executive VP of the Branded Products & Member of the Exe. Mgmt. Board · b. 1971
  • Ms. Julia Irene MachareyExecutive VP of People & Culture & Member of Management Board · b. 1977
  • Mr. Mikko KemppainenGeneral Counsel, Secretary to the Board & Member of Executive Management Board · b. 1972
  • Mr. Berkeley VincentExecutive Vice President of Innovative Medicines & Member of Management Board · b. 1977

Financials

Income Statement

Currency: EUR2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.95B1.90B311.20M683.60M710.70M771.50M849.90M917.90M980.30M1.01B1.02B1.02B1.07B1.08B977.40M1.05B1.08B1.04B1.34B1.19B1.54B1.89B
Growth (%)--2.28%-83.64%+119.67%+3.96%+8.55%+10.16%+8.00%+6.80%+2.71%+0.83%+0.03%+5.70%+1.04%-9.89%+7.52%+2.59%-3.44%+28.79%-11.27%+29.66%+22.50%
Cost of Revenue1.43B1.36B105.20M204.20M230.00M265.20M283.20M305.10M350.00M393.50M401.70M405.80M421.70M440.60M387.90M417.60M427.00M447.50M491.70M531.90M596.00M676.50M
Gross Profit516.10M542.30M206.00M479.40M480.70M506.30M566.70M612.80M630.30M613.40M613.60M609.80M651.80M644.10M589.50M633.30M651.10M593.50M849.00M657.70M946.40M1.21B
Gross Margin26.52%28.52%66.20%70.13%67.64%65.63%66.68%66.76%64.30%60.92%60.44%60.04%60.72%59.38%60.31%60.26%60.39%57.01%63.33%55.29%61.36%64.20%
Operating Expense385.00M367.00M115.10M292.60M287.20M299.40M312.50M329.90M349.40M345.70M341.20M343.20M337.20M351.10M336.70M380.50M371.00M350.20M409.40M382.80M529.80M588.00M
Operating Income131.10M175.30M90.90M186.80M193.50M206.90M254.20M282.90M280.90M267.70M272.40M266.60M314.60M293.00M252.80M252.80M280.10M243.30M439.60M274.90M416.60M625.00M
Operating Margin6.74%9.22%29.21%27.33%27.23%26.82%29.91%30.82%28.65%26.59%26.83%26.25%29.31%27.01%25.86%24.06%25.98%23.37%32.79%23.11%27.01%33.08%
EBITDA191.00M231.60M108.10M226.10M219.90M242.80M293.70M320.20M319.20M306.50M312.90M309.30M356.10M326.20M294.80M309.60M336.00M289.40M489.60M328.20M513.50M681.70M
EBITDA Margin9.81%12.18%34.74%33.07%30.94%31.47%34.56%34.88%32.56%30.44%30.82%30.45%33.17%30.07%30.16%29.46%31.17%27.80%36.52%27.59%33.29%36.08%
Net Income90.50M131.10M66.60M145.40M136.30M151.40M184.70M209.50M208.90M206.20M211.30M208.20M249.00M226.00M330.30M200.40M219.90M193.80M349.50M216.80M329.90M500.30M
Net Income Margin4.65%6.89%21.40%21.27%19.18%19.62%21.73%22.82%21.31%20.48%20.81%20.50%23.20%20.84%33.79%19.07%20.40%18.62%26.07%18.22%21.39%26.48%
R&D71.00M72.40M43.10M90.00M103.40M95.20M85.50M87.50M104.80M101.90M106.20M108.10M118.20M105.10M104.00M119.30M123.20M117.70M135.80M126.90M179.60M210.40M
R&D as % of Total Revenue3.65%3.81%13.85%13.17%14.55%12.34%10.06%9.53%10.69%10.12%10.46%10.64%11.01%9.69%10.64%11.35%11.43%11.31%10.13%10.67%11.64%11.14%
Interest Expense3.90M3.90M3.00M1.10M8.50M8.40M5.90M6.00M2.60M4.00M5.80M5.50M4.80M6.20M4.60M2.70M1.20M1.30M1.80M5.70M8.40M8.70M
Interest Expense % of Total Revenue0.20%0.21%0.96%0.16%1.20%1.09%0.69%0.65%0.27%0.40%0.57%0.54%0.45%0.57%0.47%0.26%0.11%0.12%0.13%0.48%0.54%0.46%

Balance Sheet

Currency: EUR2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.14B1.14B588.10M589.50M695.50M727.10M745.80M779.10M836.90M979.00M1.00B1.05B1.06B1.06B1.15B1.04B1.12B1.11B1.50B1.44B1.63B2.01B
Total Liabilities655.90M555.00M144.60M142.20M276.90M288.00M278.40M279.10M325.70M465.10M486.60M452.50M421.80M375.80M373.60M256.30M384.30M366.10M595.50M548.50M624.10M725.40M
Total Equity461.70M564.60M443.50M447.30M418.60M439.10M467.40M500.00M511.20M513.90M514.90M594.90M641.10M679.70M773.10M779.40M731.30M747.90M908.10M890.10M1.00B1.28B
Cash106.90M159.50M110.00M90.40M176.10M170.50M89.50M123.00M145.20M214.70M185.50M245.20M200.90M164.10M248.70M114.00M294.40M216.70M332.60M106.70M205.60M160.90M
Total Debt120.70M56.10M9.80M4.10M146.30M131.40M110.00M88.70M136.60M257.80M234.40M187.80M152.60M151.40M151.50M10.00M108.60M108.50M214.00M200.10M327.30M305.40M
Net Debt13.80M-103.40M-100.20M-86.30M-29.80M-39.10M20.50M-34.30M-8.60M43.10M48.90M-57.40M-48.30M-12.70M-97.20M-104.00M-185.80M-108.20M-118.60M93.40M121.70M144.50M

Cash Flow

Currency: EUR2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow185.30M173.30M81.60M150.90M144.40M204.60M209.10M198.90M221.00M215.20M296.70M254.90M249.10M228.40M230.90M270.80M299.10M215.70M434.40M119.00M293.40M316.80M
Investing Cash Flow-20.70M-20.80M-12.30M-21.50M-51.80M-59.50M-30.80M-43.90M-47.10M-71.30M-54.90M-42.20M-21.10M-74.90M95.40M-34.00M-39.70M-80.20M-154.30M-108.40M-85.20M-98.60M
Financing Cash Flow-197.80M-98.60M-1.40M-148.50M-4.80M-152.10M-182.20M-199.70M-152.40M-73.50M-200.50M-230.80M-237.40M-220.30M-205.30M-371.40M-115.10M-214.80M-159.80M-243.20M-108.80M-263.60M
Capital Expenditure29.30M30.30M12.30M31.00M53.80M60.70M35.40M45.50M49.10M73.30M56.40M43.20M47.70M76.50M66.80M36.20M40.70M85.00M73.10M116.80M86.90M97.60M
Free Cash Flow156.00M143.00M69.30M119.90M90.60M143.90M173.70M153.40M171.90M141.90M240.30M211.70M201.40M151.90M164.10M234.60M258.40M130.70M361.30M2.20M206.50M219.20M
Dividends Paid251.10M74.20M--141.10M134.40M155.30M177.50M199.90M183.70M176.20M183.30M183.60M218.00M203.90M211.20M211.10M211.20M211.20M224.90M228.00M231.10M
FCF to OCF84.19%82.52%84.93%79.46%62.74%70.33%83.07%77.12%77.78%65.94%80.99%83.05%80.85%66.51%71.07%86.63%86.39%60.59%83.17%1.85%70.38%69.19%
Dividend Paid to FCF160.96%51.89%--155.74%93.40%89.41%115.71%116.29%129.46%73.33%86.58%91.16%143.52%124.25%90.03%81.70%161.59%58.46%10222.73%110.41%105.43%

Earnings

Report DateNov 2, 2006Feb 6, 2007Feb 7, 2008Apr 25, 2008Oct 28, 2008Feb 6, 2009Apr 27, 2009Aug 7, 2009Oct 26, 2009Feb 9, 2010Apr 27, 2010Aug 10, 2010Oct 26, 2010Feb 9, 2011Apr 27, 2011Aug 2, 2011Oct 25, 2011Feb 7, 2012Apr 24, 2012Jul 31, 2012Oct 23, 2012Feb 5, 2013Apr 23, 2013Jul 30, 2013Oct 22, 2013Feb 4, 2014Apr 29, 2014Jul 29, 2014Oct 21, 2014Feb 4, 2015Apr 29, 2015Jul 28, 2015Oct 27, 2015Feb 2, 2016Apr 27, 2016Jul 19, 2016Oct 25, 2016Feb 8, 2017Apr 26, 2017Jul 19, 2017Oct 26, 2017Feb 7, 2018Apr 24, 2018Jul 18, 2018Oct 24, 2018Feb 6, 2019Apr 25, 2019Jul 17, 2019Oct 23, 2019Feb 5, 2020Apr 28, 2020Jul 17, 2020Oct 21, 2020Feb 9, 2021Apr 27, 2021Jul 19, 2021Oct 20, 2021Feb 10, 2022Apr 28, 2022Jul 15, 2022Oct 20, 2022Feb 9, 2023Apr 27, 2023Jul 17, 2023Oct 26, 2023Mar 20, 2024Apr 25, 2024Aug 8, 2024Oct 29, 2024Mar 20, 2025Apr 23, 2025Jul 18, 2025Oct 28, 2025Feb 4, 2026Apr 23, 2026Jul 17, 2026Oct 28, 2026
EPS Estimate-----------------------------------------------------------------------------
EPS Actual0.280.190.220.330.220.180.300.260.290.230.370.310.370.260.490.340.340.320.420.350.410.300.390.330.350.390.370.480.350.290.470.410.320.280.450.470.520.340.500.400.310.390.411.320.240.380.300.290.510.320.480.540.370.180.420.400.320.230.410.471.380.230.310.260.440.540.310.371.140.520.440.590.681.850.641.001.19
Surprise-----------------------------------------------------------------------------
Timing-----------------------------------------------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market---

Key Statistics & Ratios

Market Cap14.16B
Enterprise Value13.88B
Trailing P/E21.58
Forward P/E29.50
PEG Ratio5.73
Price / Sales6.51
Price / Book9.91
EPS4.68
Book Value9.96
Revenue (TTM)2.18B
Gross Profit (TTM)1.47B
EBITDA884.40M
Profit Margin30.26%
Operating Margin38.71%
Return on Equity54.49%
Return on Assets27.42%
Shares Outstanding31.15M
Shares Float122.99M
Beta0.24
Dividend Yield1.79%
Dividend Rate1.80
Payout Ratio38.47%

Dividends

20262×
0.90Oct 19, 20260.90Mar 25, 2026
20252×
0.82Oct 15, 20250.82Apr 4, 2025
20242×
0.81Oct 15, 20240.81Mar 21, 2024
20231×
1.60Mar 23, 2023
20221×
1.50Mar 24, 2022
20211×
1.50Mar 26, 2021
20201×
1.50May 7, 2020
20191×
1.50Mar 27, 2019
20181×
1.45Mar 21, 2018
20171×
0.20Mar 23, 2017
20161×
1.30Mar 23, 2016
20151×
1.30Mar 25, 2015
20141×
1.25Mar 26, 2014
20131×
1.30Mar 20, 2013
20121×
0.12Mar 21, 2012
20111×
0.06Apr 1, 2011
20101×
0.10Mar 25, 2010
20091×
0.95Mar 24, 2009
20081×
1.00Mar 26, 2008
20071×
1.00Apr 3, 2007
20061×
0.74Mar 22, 2006

Stock Splits

  • Sep 15, 20042:1
  • Jul 28, 19992157:1961
  • Dec 9, 19977:5
  • Nov 23, 199325035:17882